Phathom Pharmaceuticals, Inc. Common Stock
Symbol: PHAT (NASDAQ)
4.49
▲ (9.79%) 0.400
Company Description:
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
Key Stats
- Today's Open: $4.02
- Today's High: $4.55
- Today's Low: $4.035
- Today's Volume: 1.70M
- Yesterday Close: $4.085
- Yesterday High: $4.14
- Yesterday Low: $3.53
- Yesterday Volume: 1.93M
- Last Min Volume: 12
- Last Min High: $4.485
- Last Min Low: $4.485
- Last Min VWAP: $4.485
Company Profile
- Name: Phathom Pharmaceuticals, Inc. Common Stock
- Website: https://www.phathompharma.com
- Listed Date: 2019-10-25
- Location: FLORHAM PARK, NJ
- Market Status: Active
- CIK Number: 0001783183
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $219.91M
- Round Lot: 100
- Outstanding Shares: 69.81M
- Asset Type: CS
RECENT FILINGS FOR PHAT
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-05-15 | 4 | View |
| 2025-05-13 | SCHEDULE 13D/A | View |
| 2025-05-13 | 4 | View |
| 2025-05-08 | 4 | View |
| 2025-05-06 | 3 | View |
| 2025-05-01 | 10-Q | View |
| 2025-05-01 | 8-K | View |
| 2025-04-24 | SCHEDULE 13G/A | View |
| 2025-04-23 | ARS | View |
| 2025-04-23 | DEFA14A | View |
| 2025-04-23 | DEF 14A | View |
| 2025-04-16 | 4 | View |
| 2025-04-16 | 3 | View |
| 2025-04-16 | 8-K | View |
| 2025-04-08 | 4 | View |
| 2025-04-03 | 4 | View |
| 2025-04-03 | 3 | View |
| 2025-04-03 | S-8 | View |
| 2025-04-01 | 8-K | View |
| 2025-03-21 | 4 | View |
Latest News on PHAT